TGL WHAAAAAAAT! Alerts, thoughts, discussion. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SSP who wrote (73470)	12/6/2000 10:48:37 AM
From: Jim Bishop	Read Replies (1) of 150070

United Therapeutics Announces Stock Repurchase Program SILVER SPRING, Md., Dec. 5 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR - news) announced today that its Board of Directors approved a stock repurchase program of up to 3,000,000 shares of its outstanding stock over the next six months. It is anticipated that these purchases will be made at management's discretion in the open market and/or through privately negotiated transactions, subject to market conditions. United Therapeutics further announced that some members of its Board of Directors and senior management also plan to make market purchases of the company's stock. There are approximately 20,185,000 shares of United Therapeutics common stock outstanding. ``Our board of directors and management believe that United Therapeutics' stock is substantially undervalued by the market and we decided to take advantage of this opportunity to capture some of this value for our continuing shareholders,'' said Martine Rothblatt, Chairman and CEO of United Therapeutics. ``With approximately $230 million in cash, cash equivalents and investments, our financial position is sufficiently strong to allow for both this stock repurchase and our continued drug development program. The board's decision to initiate a stock repurchase program underscores our belief that United Therapeutics' shares are substantially undervalued and demonstrates our commitment to enhance shareholder value.'' United Therapeutics is a biotechnology company focused on combating cardiovascular, inflammatory and infectious diseases with unique therapeutic products. SOURCE: United Therapeutics Corporation

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next